CAR T-cell therapy enables chemo-free treatment of R/R follicular lymphoma
While most patients with follicular lymphoma (FL) can expect to live for another 20 years after diagnosis, a significant minority relapse within 2 years and have considerably worse prognosis. At a symposium organized by the Hong Kong Society of Haematology, Professor Catherine Thieblemont of the Haemato-Oncology Department, Hôpital Saint-Louis, Paris, France, a key investigator on the ELARA trial, reviewed chemotherapy-free options for relapsed/refractory (R/R) FL and shared her experience of using a chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel, in a heavily pretreated patient.

New Molecule

6 New

New Indication

5 New

New Dosage Strength

1 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in